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The advance in cancer early detection and cancer treatment have led to the rapid growth in 
the number of cancer survivors. It is good news that cancer is more survivable than ever, 
however, it also brings new challenges. Cancer survivors are exposed to the risk of a second 
primary cancer. In Chapter 1 and Chapter 3, we investigated the survival of lung cancer patients 
with a history of previous cancer. Another challenge that cancer survivors need to face is the 
follow-up care. Many survivors found that they are “lost in transition” from cancer patients to 
cancer survivors. In Chapter 2, we investigated the patterns of use and impact on emergency 
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Surprisingly, survival from a diagnosis of lung cancer has been found to be longer for those 
who experienced a previous cancer than for those with no previous cancer. A possible 
explanation is lead-time bias, which, by advancing the time of diagnosis, apparently extends 
survival among those with a previous cancer even when they enjoy no real clinical advantage. 
We propose a discrete parametric model to jointly describe survival in a no-previous-cancer 
group (where, by definition, lead-time bias cannot exist) and in a previous-cancer group (where 
lead-time bias is possible). We model the lead time with a negative binomial distribution and the 
post–lead-time survival with a linear spline on the logit hazard scale, which allows for survival to 
differ between groups even in the absence of bias; we denote our model Logit-Spline/Negative 
Binomial. We fit Logit-Spline/Negative Binomial to a propensity-score matched subset of the 
Surveillance, Epidemiology, and End Results–Medicare linked data set, con-ducting sensitivity 
analyses to assess the effects of key assumptions. With lung cancer–specific death as the end 
point, the estimated mean lead time is roughly 11 months for stage I&II patients; with overall 
survival, it is roughly 3.4 months in stage I&II. For patients with higher-stage lung cancers, the 
mean lead time is 1 month or less for both outcomes. Accounting for lead-time bias reduces the 





Lung cancer, with 5-year survival less than 20%, is the leading cause of cancer-related death 
in the United States.1 It mainly affects older people, many of whom have experienced previous 
cancers and other chronic diseases. Indeed, in 1992-2009 linked Surveillance, Epidemiology, and 
End Results (SEER) – Medicare data, the proportion of lung cancer patients who were survivors 
of another cancer at the time of their lung cancer diagnosis ranged from 14% to 21%, depending 
on stage.2-4 Because a previous diagnosis of cancer is thought to adversely affect clinical 
outcomes, it is a common exclusion criterion in lung cancer clinical trials, blocking up to 18% of 
otherwise eligible patients from participation.5 Yet surprisingly, several studies have reported 
that among newly diagnosed lung cancer patients aged 66 and older, those with a previous cancer 
do not have worse survival than those with no previous diagnosis; indeed, they often do 
better.2,3,6-8 For example, Laccetti et al2 observed that among patients with a newly diagnosed 
stage IV lung cancer, those with a previous cancer diagnosis had longer all-cause survival and 
lung cancer–specific survival than similar patients who had not had a previous cancer.  
A possible explanation is lead-time bias. Lead time is the length of time between the moment 
a disease becomes detectable (that is, by tests applied to an asymptomatic person) and the 
moment it becomes clinically manifest. If a lead time advances the date of diagnosis, the survival 
time will appear to be longer, even if earlier detection offers no clinical benefit. It is plausible 
that a lead-time bias could exist in the case of a cancer survivor, likely as a result of enhanced 
surveillance or the patient's seeking prompt evaluation of symptoms that could represent a 
subsequent tumor. 
Statisticians have long recognized the potential biasing effects of early detection on apparent 
cancer survival9-11; consequently, statistical models of lead-time bias largely assume the 
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background of a cancer screening program.12-14 In this paper, we propose a parametric method 
for estimating lead-time bias that has arisen not from formal screening but instead from whatever 
additional surveillance that patients and their doctors have implemented following a previous 
cancer diagnosis. We suppose that one has data from newly diagnosed lung cancer patients, some 
with a history of cancer (the Previous group), and some without (the No-Previous group). We 
assume that only the Previous group is subject to the bias, which takes the form of a random lead 
time that is added to the latent survival that the patient would have experienced under usual care. 
In the No-Previous group, we see the natural survival only, untainted by bias. To model these 
variables, we describe the logit of the post–lead-time death hazard by a spline, allowed to differ 
between Previous and No-Previous groups, and the lead time as an independent negative 
binomial (NB); we denote our model LS/NB, for Logit-Spline/Negative Binomial. These 
assumptions give us the means to construct parsimonious models. We apply the method to new 
lung cancer diagnoses from a large national database. 
1.2 The Lung Cancer Data 
We extracted our data from the linked SEER-Medicare database. We included patients 66 
years or older with primary lung cancer diagnosed between 2000 and 2011, an interval that 
represents the most recent data available and produces a large sample size. All patients had full 
coverage of Medicare Parts A and B from 1 year before to 1 year after the lung cancer diagnosis. 
We included only patients with either non–small cell (NSCLC) or small cell (SCLC) lung cancer 
histology. To ensure complete claims data, we excluded patients who participated in health 
maintenance organizations and those with only autopsy or death certificate records. We also 
omitted patients with incomplete diagnosis or death dates or discrepancies in SEER and 
Medicare birth dates of a year or more. 
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To preserve patient anonymity, SEER-Medicare death and diagnosis data include only the 
month and year of these events. Thus, survival is measured as the interval, in integer months, 
between the month of diagnosis and the month of death, and the survival times are effectively 
discrete. This creates the possibility of survival times of 0 months. 
We conducted analyses stratified by the stage of the diagnosed lung cancer, for 2 reasons: 
First, survival varies greatly by stage, and thus, the strata represent clinically distinct groups. 
Second, symptoms and tumor aggressiveness differ by stage, in that earlier stages are less likely 
to be symptomatic and therefore more susceptible to lead-time bias. We classified patients by the 
American Joint Committee on Cancer criteria into stages I&II, III, and IV. We combined stages I 
and II because they are more similar to each other than to higher stages, and they represent a 
relatively small proportion of lung cancer (in our data, stage II is only around 3% of all cases).4 
We excluded the heterogeneous “unstaged” stratum. 
We used propensity-score matching to reduce confounding from differences in baseline 
mortality risk between the Previous and No-Previous groups. We computed a propensity score 
predicting previous cancer status from available covariates: age, sex (F, M), race/ethnicity 
(white, black, Hispanic, other), marital status (married, separated/divorced/widowed, single, 
unknown), histology (SCLC, NSCLC-adenocarcinoma, NSCLC-squamous, NSCLC-other), 
Charlson comorbidity score (0, 1, 2+, not available), Medicaid status (Y, N), and lung cancer 
treatment (surgery only, chemotherapy only, radiation only, ≥2 treatments, no 
surgery/chemo/radiation). As there were fewer patients in the Previous group, we paired a single 
Non-Previous patient with each Previous patient by nearest-neighbors matching. 
The Institutional Review Board of the University of Texas Southwestern Medical Center 




1.3.1 The LS/NB Model 
In the No-Previous group, we take the observed survival time to represent the actual survival 
time from clinical diagnosis, which we denote the post–lead-time survival; we label this variable 
𝑋𝑁. In the Previous group, we assume that the observable survival time 𝑍 is the sum of 2 
independent, latent components: the lead time 𝑇 and the post–lead-time survival 𝑋𝑃; that is, 𝑍 =
𝑇 + 𝑋𝑃.15 We assume moreover that 𝑋𝑁, 𝑋𝑃, and 𝑇 take values in the nonnegative integers. Our 
strategy is to assume flexible models for 𝑋𝑁 and 𝑋𝑃 that differ by at most a single parameter. 
Because 𝑋𝑁 is fully observed (except for censoring), we can use the hypothesized similarity of 
𝑋𝑁 and 𝑋𝑃 as a lever to extract information on the distribution of lead times. 
We first consider the distribution of post–lead-time survival in the No-Previous group, 
labeled 𝑋𝑁. We denote the probability mass function of 𝑋𝑁 as 𝑓𝑁(𝑥) = Pr⁡[𝑋𝑁 = 𝑥], its survival 
function as 𝑆𝑁(𝑥) = Pr[𝑋𝑁 ≥ 𝑥] = ∑ 𝑓𝑁(𝑗)∞𝑗=𝑥 , and its hazard function as ℎ𝑁(𝑥) =
Pr[𝑋𝑁 = 𝑥|𝑋𝑁 ≥ 𝑥] = 𝑓𝑁(𝑥) 𝑆𝑁(𝑥)⁄ , for 𝑥 ∈ (0, 1, 2,⋯ ). 
Attempts to model survival with standard discrete and continuous distributions revealed 
substantial lack of fit in this large database. A purely nonparametric model was also unsuccessful 
(see the discussion below). Thus, there was a need for an intermediate approach — a survival 
model that offers reasonable flexibility with a modest number of parameters. Plots of the logit of 
the empirical hazard against time revealed that this function is amenable to description with a 
linear spline having a modest number of knots.16 Thus, for the No-Previous group, we assume 
the logit hazard is of the form 
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𝜆𝑁(𝑥; 𝛽) ≡ 𝑙𝑛
ℎ𝑁(𝑥)
1 − ℎ𝑁(𝑥)
= 𝛽0 + 𝛽1𝑥 + ∑ 𝛽𝑗(𝑥 − 𝑘𝑗−1)+
𝑚+1
𝑗=2
, 𝑥 ∈ {0, 1, 2,⋯ }, 
 
where 0 < 𝑘1 < ⋯ < 𝑘𝑚 are preselected knots and (𝑢)+ = max⁡(0, 𝑢We assume moreover that 
the post–lead-time survival in the Previous group differs from that in the No-Previous group 
according to a proportional odds model on the hazard function. That is, we take the logit hazard 
for the Previous group 𝜆𝑃(𝑥) to be 
𝜆𝑃(𝑥; 𝛽, 𝛾) ≡ 𝑙𝑛
ℎ𝑃(𝑥)
1 − ℎ𝑃(𝑥)
= 𝜆𝑁(𝑥; 𝛽) + 𝛾, 𝛾 ∈ (−∞,∞). 
The odds ratio (OR) of hazards comparing the Previous group with the No-Previous group is 
therefore OR = exp⁡(𝛾).  
In computations, we can begin with the logit hazard 𝜆(𝑥) and compute the hazard as ℎ(𝑥) =
1/[1 + exp⁡(−𝜆(𝑥))], the survival function as 𝑆(𝑥) = ∏ [1 − ℎ(𝑗)]𝑗<𝑥 , and the probability mass 
function as 𝑓(𝑥) = ℎ(𝑥)𝑆(𝑥). 
As indicated above, we take survival 𝑍 in the Previous group to be the sum of a lead time 𝑇 
and the post–lead-time survival 𝑋𝑃. Because 𝑇 is a latent variable, it is convenient to model it 
with a low-parameter discrete distribution. We chose the NB, as it has only 2 parameters but can 
present unimodal shapes and imposes a less strict functional relationship between mean and 
variance than the Poisson. Specifically, we assume that lead time follows the NB distribution 
𝑇~NB(𝜌, 𝜎), with probability mass function parameterized as 
𝑓𝑇(𝑡; 𝜌, 𝜎) =
Γ(𝑡 + 𝜌)
Γ(𝜌)Γ(𝑡 + 1)
𝜎𝜌(1 − 𝜎)𝑡, 𝑡 ∈ (0, 1, 2,⋯ ) 
for 𝜌 > 0, 0 < 𝜎 ≤ 1. The probability mass function for 𝑍 is the convolution 
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𝑓𝑍(𝑧) =∑𝑓𝑇(𝑡)𝑓𝑃(𝑧 − 𝑡)
𝑧
𝑡=0
, 𝑧 ∈ (0,1,2,⋯ ), 
where 𝑓𝑇(∙) and 𝑓𝑃(∙) are the probability mass functions of 𝑇and 𝑋𝑃, respectively. 
With this large data set of discrete event times, we can hasten computations by structuring 
the data in a frequency table. We categorize data by group (Previous or No-Previous), duration 
of survival, and event status (censored or dead), as shown in Table 1-1. The index 𝑥 represents 
the possible survival times and runs from 0 to 𝑀; 𝑛𝑥
(𝐴)represents the number of subjects alive 
going into time 𝑥 in group 𝐴; 𝑑𝑥
(𝐴) represents the numbers of subjects dying at time 𝑥 in group 𝐴; 
and 𝑐𝑥





(𝐴) , 𝑥 = 1,⋯ ,𝑀. An empirical estimate of the hazard at time 𝑥 in the No-Previous group is the 





(𝑁) , 𝑥 = 0,⋯ ,𝑀. 
 
Table 1-1. Tabular representation of the Surveillance, Epidemiology, and End Results–Medicare 
lung cancer data 









































Denote the probability mass function and survival function at time 𝑥 in the No-Previous 
group as 𝑓𝑋(𝑥; 𝛽) and 𝑆𝑋(𝑥; 𝛽), respectively. Using our tabular notation, the loglikelihood for 𝛽 
in the No-Previous group is 
ln𝐿𝑁(𝛽) =∑[𝑑𝑥
(𝑁) ln 𝑓𝑋(𝑥; 𝛽) + 𝑐𝑥




Similarly, let 𝑓𝑍(𝑧; 𝛽, 𝛾, 𝜌, 𝜎) and 𝑆𝑍(𝑧; 𝛽, 𝛾, 𝜌, 𝜎) be the probability mass and survival functions, 
respectively, for the Previous group, derived form Equation 1. The loglikelihood contribution for 
𝛽, 𝛾 (the log OR for the post-lead-time survival) and 𝜌, 𝜎 (the parameters of the lead-time 
distribution) from the Previous group is then  
ln𝐿𝑃(𝛽, 𝛾, 𝜌, 𝜎) =∑[𝑑𝑧
(𝑃) ln 𝑓𝑍(𝑧; 𝛽, 𝛾, 𝜌, 𝜎) + 𝑐𝑧




Combining these expressions, the loglikelihood form the entire data set is 
ln𝐿(𝛽, 𝛾, 𝜌, 𝜎) = ln𝐿𝑁(𝛽) + ln𝐿𝑃(𝛽, 𝛾, 𝜌, 𝜎). 
We obtain the maximum likelihood estimate (MLE) ?̂?, 𝛾, ?̂?, ?̂? by maximizing Equation 3 
numerically using the limited-memory Broyden-Fletcher-Goldfard-Shanno method with box 
constraints, a quasi-Newton algorithm implemented in R function optim().17 We estimated the 
mean lead time 𝐸(𝑇) as ?̂?(1 − ?̂?) ?̂?⁄  and the OR as exp⁡(𝛾), and we construct confidence 
intervals (CIs) for these parameters by the delta method. R code is available from the first author. 
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1.3.3 Sensitivity Analysis 
We conducted a set of sensitivity analyses to evaluate robustness of results to key model 
assumptions. 
The first analysis assessed the effect of varying assumptions about each part of the post-lead-
time survival model on the parameters of the other part. We first assumed that there is no lead 
time (𝑇 ≡ 0) and estimated the corresponding difference in survival between the Previous and 
No-Previous groups (now completely described by the OR). Next, we assumed fixed values of 𝛾 
(the log OR for the survival difference) and obtained the corresponding estimates of the 
remaining parameters 𝛽, 𝜌, 𝜎(𝛾)̂ . 
The second analysis assessed robustness to the assumed independence of 𝑋𝑃 and 𝑇. Using 
our MLE as the truth, we simulated survival time 𝑋𝑁 in the No-Previous group through its spline 
model. For the Previous group, we assumed the MLE marginal distributions and simulated 𝑋𝑃 
and 𝑇 from a bivariate normal copula with underlying correlation 𝜃, generating 𝑍 = 𝑋𝑃 + 𝑇. 
After simulating data for both groups, we estimated LS/NB assuming independence of lead time 
and survival, comparing the estimated mean lead time under the varying assigned correlations. 
The third analysis examined the effect of the assumed distribution of lead time 𝑇. In addition 
to the NB, we evaluated a range of models including the geometric, Poisson, zero-inflated 
Poisson, zero-inflated NB, and a nonparametric (multinomial) distribution that assumes support 
on a small number of integers but is otherwise unrestricted. We calculated MLEs of 𝐸(𝑇) and 
OR under each model and compared fits via the Akaike information criterion (AIC). 
In a final sensitivity analysis, we compared results from the propensity-score-matched 




1.4.1 Preliminary Analyses 
We identified 215 718 SEER-Medicare lung cancer diagnoses, of whom 22% were stage 
I&II, 24% stage III, and 39% stage IV; the remaining 15% were unstaged. Roughly 20% had a 
previous cancer (Table 1-2). 
We first analyzed the data by computing mean survival (restricted to 160 month), estimating 
a proportional hazards model with Previous group status as the sole covariate, and comparing the 
groups by a logrank test; results appear in Table 1-3. For lung cancer mortality, mean survival is 
greater in the Previous group in each stage, with hazard ratios ranging from 0.82 to 0.78. For all-
cause mortality, mean survival is shorter in the Previous group in stage I&II (HR = 1.05) but 
longer in the higher stages (HR = 0.94 in stage III and HR = 0.90 in stage IV). Kaplan-Meier 
survival plots appear in Figure 1-1. 
Figure 1-2 displays estimated hazard functions for lung cancer and all-cause death in the No-
Previous group, stratified by lung cancer stage. We computed the “raw” estimates by Equation 2 
and the “LS/NB” estimates by fitting the model to the entire matched data set. We placed knots 
at𝑘1 = 1, 𝑘2 = 5, 𝑘3 = 50, and 𝑘1 = 100, where visual inspection suggested a possible change 
in the slope of the logit hazard. Evidently the model offers a good fit. Table 1-4, which compares 
Kaplan-Meier estimates of the survival function with estimates under the spline model for the 





Table 1-2. Surveillance, Epidemiology, and End Results–Medicare data: count of patients by 
stage and previous cancer diagnosis 
Stage Previous, % No-Previous, % Total 
Original data          
I&II 10 187 (22) 36 402 (78) 46 589  
III 8474 (16) 43 841 (84) 52 315       
IV 12 716 (15) 70 852 (85) 83 568  
Matched data          
I&II 10 187 (50) 10 187 (50) 20 374  
III 8473* (50) 8473 (50) 16 946  
IV 12 715* (50) 12 715 (50) 25 430  
*Omitting subjects who had missing marital status. 
 
Table 1-3. Surveillance, Epidemiology, and End Results–Medicare lung cancer data: summary of 
mortality in the matched data 
Stage Mean Survival in Months* Previous No-Previous† HR (95% CI) Logrank P 
Death from lung cancer 
I&II 90.4 83.0 0.82 (0.79-0.86) < .0001 
III 33.8 26.3 0.80 (0.77-0.83) < .0001 
IV 16.5 10.8 0.78 (0.76-0.80) < .0001 
Death from any cause 
I&II 52.9 56.4 1.05 (1.02-1.09) 0.0033 
III 19.1 18.1 0.94 (0.91-0.97) < .0001 
IV 9.4 8.1 0.90 (0.88-0.93) < .0001 
Abbreviations: CI, confidence interval; HR, hazard ratio from a Cox model. 
*Restricted mean with upper limit = 160 months 
†Reference group 
1.4.2 LS/NB Model Estimates 
We applied LS/NB to the matched data set, estimating simultaneously the spline coefficients, 
OR, and the lead-time parameters. The estimated LS/NB survival curves in Figure 1-3 agree well 
with the superimposed Kaplan-Meier curves; the divergence of the empirical and estimated 
curves in the right tail partly reflects plotting survival on the log scale, which magnifies 
differences at small values, and partly the reduced precision in this range. 
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Maximum likelihood estimates of 𝐸(𝑇) and OR appear in the top panel of Table 1-5. For 
lung cancer mortality, the estimated 𝐸(𝑇) for patients with stage I&II lung cancer in the Previous 
group is 11.3 months; estimated mean lead times in stages III and IV are roughly 1 month and 1 
week, respectively. Even allowing for a potential lead-time bias, the ORs are less than 1 
(significantly so in stages III and IV); thus, accounting for lead-time bias does not nullify the 
beneficial effect of having had a previous cancer on lung cancer mortality. As mean lead time 
declines with advancing stage, the effect of surviving a previous cancer increases, with the 
greatest survival advantage (OR = 0.79; 95% CI, 0.77-0.82) appearing in stage IV. 
For all-cause death (Figure 1-3, right panel; Table 1-5, top right), the estimated mean lead 
times are 3.4, 1.1, and 1.1 months for patients in stages I&II, III, and IV, respectively. In stage 
I&II, accounting for lead-time bias accentuates an already statistically significant overall survival 
advantage for the No-Previous group. For stages III and IV, incorporating lead time in the model 
renders the OR indistinguishable from unity. Thus, for all-cause death, the apparent survival 
advantage in the Previous group with stages III and IV cancer may well reflect a modest lead-
time bias. In stage I&II, the survival advantage in the No-Previous group is larger than the 
estimated hazard ratio of 1.05 from the Cox model. 
As demonstrated in Figure 1-3 and Table 1-5, the survival advantage of the Previous group is 
only apparent when one censors non-lung cancer deaths; for overall survival, the No-Previous 
group does slightly better in stage I&II and roughly the same in stages III and IV, even after 
accounting for lead time. Figure 1-4, which displays cumulative incidence curves18 of death from 
cancer and other causes in stage I&II and stage IV, explains this observation (we omit stage III, 
which is similar to stage IV). The curves, unadjusted for lead-time bias, show that subjects in the 
Previous group at every stage have a lower rate of death from lung cancer but a higher rate of 
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death from other causes. In stage I&II, the risk of lung cancer death is low in both groups and 
similar to the risk of death from other causes; thus, overall death rates slightly favor the No-
Previous group. In stage IV, the risk of lung cancer mortality is the dominant hazard component; 
thus, there is a modest advantage for the Previous group in overall mortality, mirroring the 




Figure 1-1. Kaplan-Meier survival curves (on the log scale) for newly diagnosed lung cancer 





Figure 1-2. Raw (KM) and estimated hazard functions of lung cancer–specific and overall 




Table 1-4. Estimated lung cancer–specific and all-cause survival in months (%) for the No-
Previous group 
 Lung Cancer-Specific Survival, % All-Cause Survival, % 
Stage I&II III IV I&II III IV 
Time KM LS KM LS KM LS KM LS KM LS KM LS 
0 99.1 99.0 94.4 94.4 91.7 91.7 98.4 98.4 92.6 92.4 89.3 89.3 
1 97.3 97.2 84.7 85.2 74.9 74.8 95.7 95.4 81.0 81.7 70.1 70.1 
3 93.7 93.8 71.9 71.5 54.0 54.0 90.3 90.4 67.0 66.6 48.0 47.9 
5 90.8 90.6 63.5 62.2 42.3 42.4 86.3 86.3 57.9 56.8 36.2 36.5 
40 59.8 59.7 17.2 16.7 5.0 4.8 47.3 46.9 11.9 11.5 3.2 3.0 
80 46.4 46.5 10.1 10.1 2.1 2.3 28.6 28.8 5.1 5.2 1.0 1.1 
100 42.1 42.5 8.6 8.6 1.8 1.9 22.7 22.7 3.6 3.5 0.8 0.8 
120 39.7 39.2 7.6 7.6 1.2 1.5 17.6 17.6 2.6 2.5 0.4 0.5 
140 36.2 36.5 7.3 7.0 0.8 0.8 13.5 13.2 2.1 1.9 0.2 0.2 
 
1.4.3 Sensitivity Analyses 
Our initial sensitivity analysis estimated the OR assuming no lead time (𝑇 ≡ 0) and 
estimated 𝐸[𝑇] while holding OR fixed at a range of likely values. Results appear in Table 1-6. 
For lung cancer death, with no lead-time bias, the estimated OR is 0.82, 0.80, and 0.77 for stages 
I&II, III, and IV, respectively (note the similarity to the hazard ratios in Table 1-3). As we allow 
the OR to increase to 1.2, the mean lead time rises to as high as 44 months for stage I&II and 7.7 
months for stage IV (Table 1-6 and Figure 1-5). This is to be expected, because the larger the 
OR, the greater must be the lead-time bias to compensate for it. If the entire lung cancer survival 
difference is explained by lead time, that is, if OR = 1, then the mean lead time is estimated to be 
15.4, 8.5, and 5.1 months for stages I&II, III, and IV, respectively. Thus, a substantial mean lead 
time—more than 1 year in stage I&II — is needed to nullify any apparent positive effect of 
previous cancer on lung cancer survival. For all-cause death with no lead time, we estimate the 
OR to be 1.05, 0.94, and 0.90 for stages I&II, III, and IV, respectively. The estimated 𝐸[𝑇] also 
increases as OR increases (Figure 1-5, right panel) but less dramatically than when lung cancer-
specific death is the end point. A recurring theme of the analysis is that ?̂?[𝑇] declines as the 
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stage increases. This is reasonable, as we expect higher-stage tumors to progress more rapidly 





Figure 1-3. Estimated survival functions (on the log scale) by Kaplan-Meier (KM) and the Logit-
Spline/Negative Binomial (LS/NB) method, stratified by stage 
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The second analysis evaluated sensitivity to the assumed independence between 𝑇 and 𝑋𝑃 by 
simulating data with marginal distributions similar to those in our lung cancer death data but 
with correlation of 𝑇 and 𝑋𝑃 induced by a normal copula. Results appear in Figure 1-6. With data 
generated under independence, ?̂?[𝑇] is 9.97 (95% CI, 7.00-12.94), 1.22 (95% CI, 0.80-1.63), and 
0.40 (95% CI, 0.15-0.65) months for stages I&II, III, and IV, respectively. Failure to account for 
correlation induces a negative bias when the correlation is positive and vice versa. The trend is 
most evident in stage I&II, where lead time is longest. Because positive correlation of 𝑇 and 𝑋𝑃 
is the more plausible alternative to independence, a faulty assumption of independence will 
likely lead to underestimation of 𝐸[𝑇]. Xu et al observed a similar tendency in a nonparametric 
model of breast screening.19 For stage I&II, ?̂?[𝑇] lies in the 95% CI (red dash-dotted line) under 
independence if the correlation is in the range (-0.2, 0.1). For stage IV, even if the correlation is 
as large as 0.4, ?̂?[𝑇] is still within the 95% CI under independence. Thus, an incorrect 
assumption of independence can affect results, most likely leading to a negative bias, but the 
correlation must be substantial for this to occur. One can avoid this bias by conditioning on 
factors that confound the relationship between 𝑋𝑃 and 𝑇. One can also attempt to model the 
correlation, but as only the sum of 𝑇 and 𝑋𝑃 is ever observed, it seems unlikely that it will be 
possible to estimate such a model robustly. 
Third, we evaluated sensitivity to the assumed lead-time distribution by estimating 
parameters under a range of models for 𝑇: NB, geometric, Poisson, zero-inflated Poisson, zero-
inflated NB, and a nonparametric distribution with mass at (0, 1,⋯ , 15) for stage I&II or 
(0, 1,⋯ , 5) for stage III and stage IV. In Table 1-7, we present for each model ?̂?[𝑇], OR̂, the 
first few values of the probability mass function of 𝑇, and the AIC. Among the parametric 
distributions, the geometric, Poisson, and zero-inflated Poisson never fit well; they give larger 
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AIC and usually underestimate both 𝐸[𝑇] and OR. Zero-inflated NB gives results similar to NB, 
although the latter has lower AIC. All estimated mass functions assign highest probability to 𝑇 =
0; evidently, the important difference is that NB permits a longer tail and therefore a potentially 
higher mean. The mean lead time is sensitive to model assumptions, the OR less so. Thus, it 
appears that NB is a satisfactory model for reasons of flexibility and parsimony, although users 
must anticipate some sensitivity in the estimated⁡𝐸[𝑇]. 
Finally, we estimated the model on the entire data set; see the bottom panel of Table 1-5. 
Compared with the matched analysis, estimates of OR change by no more than about 1%. 
Estimates of 𝐸[𝑇] are less robust, possibly changing by up to a half-month but never leading to a 
qualitative difference in interpretation. Confidence intervals are narrower thanks to the larger 
sample size. 
 
Table 1-5. Estimated mean lead time E[T] (month) and OR, by cause of death and stage 
 Lung Cancer-Specific Mortality All-cause Mortality 
Stage ?̂?[𝑇] (95% CI) OR̂ (95% CI) ?̂?[𝑇] (95% CI) OR̂ (95% CI) 
Matched sample 
I&II 11.3 (3.8-33.3) 0.96 (0.86-1.08) 3.4 (1.1-5.8) 1.14 (1.08-1.21) 
III 1.1 (0.5-1.7) 0.85 (0.82-0.88) 1.1 (0.5-1.7) 1.00 (0.96-1.03) 
IV 0.3 (0.02-0.5) 0.79 (0.77-0.82) 1.1 (0.4-1.7) 1.00 (0.96-1.04) 
Unmatched sample 
I&II 11.2 (2.4-20.1) 0.96 (0.89-1.05) 3.5 (1.9-5.1) 1.14 (1.10-1.18) 
III 0.7 (0.2-1.1) 0.84 (0.82-0.86) 0.9 (0.2-1.6) 1.00 (0.96-1.04) 
IV 0.4 (0.2-0.6) 0.80 (0.78-0.82) 0.9 (0.3-1.5) 0.99 (0.94-1.05) 
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Figure 1-4. Cumulative incidence curves for stage I&II and stage IV (stage III is similar to stage 
IV) 
 
Table 1-6. Sensitivity analysis of estimates of OR (assuming 𝑇 ≡ 0) and mean lead time 𝐸(𝑇) 
(for fixed OR) 
 Lung Cancer Mortality All-Cause Mortality 
Stage OR (SE) ?̂?[𝑇] (SE) OR (SE) ?̂?[𝑇] (SE) 
I&II 0.82 (0.013) 0 1.05 (0.013) 0 
 0.90 5.0 (1.1) -- -- 
 1.00 15.4 (2.6) -- -- 
 1.10 28.6 (3.2) 1.10 2.4 (0.4) 
 1.20 44.4 (3.2) 1.20 5.9 (0.8) 
III 0.80 (0.011) 0 0.94 (0.011) 0 
 0.90 2.2 (0.5) -- -- 
 1.00 8.5 (1.2) 1.00 1.1 (0.2) 
 1.10 14.4 (1.4) 1.10 3.2 (0.4) 
 1.20 18.8 (1.4) 1.20 5.5 (0.4) 
IV 0.77 (0.0082) 0 0.90 (0.0087) 0 
 0.80 0.3 (0.1) -- -- 
 0.90 2.9 (0.4) -- -- 
 1.00 5.1 (0.4) 1.00 1.1 (0.1) 
 1.10 6.6 (0.4) 1.10 2.1 (0.1) 
 1.20 7.7 (0.4) 1.20 3.0 ()0.1 
Abbreviations: OR, odds ratio; SE, standard error. Figures in italic are fixed in the sensitivity analysis. 
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Figure 1-5. Estimated mean lead time (in month) as a function of odds ratio (OR), by stage 
 





Table 1-7. Sensitivity to the assumed lead-time distribution 
Stage Parameter NB Geometric Poisson ZIP ZINB NP 
I&II ?̂?[𝑇]  11.3 1.42 0.35 0.40 8.39 2.24 
 OR̂  0.96 0.84 0.82 0.82 0.94 0.87 
 Pr⁡[𝑇 = 0]  0.640 0.704 0.704 0.712 0.677 0.741 
 Pr⁡[𝑇 = 1]  0.059 0.208 0.247 0.195 0.053 0.043 
 Pr⁡[𝑇 = 2]  0.032 0.062 0.043 0.071 0.029 0.023 
 Pr⁡[𝑇 = 3]  0.022 0.018 0.0051 0.017 0.020 0.016 
 Pr⁡[𝑇 = 4]  0.017 0.0054 4.4e-4 0.0031 0.016 0.012 
 Pr⁡[𝑇 = 5]  0.014 0.0016 3.1e-5 4.6e-4 0.013 0.010 
 AIC 85142.4 85159.0 85160.0 85161.3 85143.8 85175.7 
III ?̂?[𝑇]  1.11 1.02 0.0064 0.019 0.83 0.57 
 OR̂  0.85 0.80 0.80 0.80 0.63 0.83 
 Pr⁡[𝑇 = 0]  0.828 0.983 0.994 0.981 0.860 0.829 
 Pr⁡[𝑇 = 1]  0.051 0.016 0.0063 0.018 0.047 0.048 
 Pr⁡[𝑇 = 2]  0.026 2.7e-4 2.0e-5 3.3e-4 0.024 0.025 
 Pr⁡[𝑇 = 3]  0.017 4.4e-6 4.2e-8 3.8e-6 0.015 0.0062 
 Pr⁡[𝑇 = 4]  0.012 7.2e-8 6.7e-11 3.4e-8 0.010 0.0046 
 Pr⁡[𝑇 = 5]  0.0092 1.2e-9 8.6e-14 2.4e-10 0.0078 0.087 
 AIC 94836.9 94851.2 94850.7 94853.5 94839.8 94834.8 
IV ?̂?[𝑇]  0.28 1.02 0.013 0.011 0.25 0.20 
 OR̂  0.79 0.77 0.77 0.77 0.79 0.79 
 Pr⁡[𝑇 = 0]  0.925 0.984 0.986 0.989 0.927 0.924 
 Pr⁡[𝑇 = 1]  0.029 0.016 0.013 0.011 0.030 0.029 
 Pr⁡[𝑇 = 2]  0.013 2.6e-4 9.0e-5 8.5e-5 0.014 0.013 
 Pr⁡[𝑇 = 3]  0.0081 4.3e-6 4.0e-7 4.5e-7 0.0081 0.0082 
 Pr⁡[𝑇 = 4]  0.0054 7.1e-8 1.4e-9 1.8e-9 0.0054 0.0055 
 Pr⁡[𝑇 = 5]  0.0039 1.2e-9 3.7e-12 1.8e-9 0.0038 0.019 
 AIC 128990.1 128993.7 128993.7 128995.6 128992.0 128993.5 
Abbreviations: AIC, Akaike information criterion; NB, negative binomial; NP, nonparametric with support at 
(0,1,…,15) for stage I&II or (0,1,…,5) for stage III and stage IV; ZINB, zero-inflated NB; ZIP, zero-inflated 
Poisson. 
Underlined value is the smallest for models in that stratum. 
 
1.5 Discussion 
1.5.1 Summary and Context 
Our proposed LS/NB model allows estimation of the mean lead time in cancer patients who 
have a previous diagnosis of another cancer. Applying it to SEER-Medicare data with lung 
cancer–specific survival as the outcome, estimated mean lead times are roughly 11 months for 
stage I&II lung cancer and around 1 month or less for higher stages. For death from any cause, 
the estimated mean lead times are roughly 3 months for stage I&II and 1 month for higher stages. 
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Even after accounting for lead time, the Previous group has a lower lung cancer mortality hazard 
in all stages, statistically significantly so in stages III and IV. For all-cause mortality, accounting 
for lead time leaves survival slightly worse in the Previous group for stage I&II and practically 
equal to No-Previous survival in more advanced stages. 
Most discussion of lead-time bias assumes a context of cancer screening; to our knowledge, 
this is the first analysis of lead time as it may arise from idiosyncratically enhanced surveillance 
in cancer survivors. Walter and Stitt proposed modeling the survival of screen-detected cases by 
the hazard function; their analysis requires specification of the duration of the detectable 
preclinical phase and assumptions of independent, exponential distributions for the lead time and 
the total survival time after diagnosis.15 Xu and Prorok assumed that the lead time is exponential 
but used a nonparametric method to estimate post–lead-time survival.20 Duffy et al assumed an 
exponential distribution of the lead time, adjusting the survival times of the screen-detected cases 
by subtracting an estimated conditional mean lead time.21 
1.5.2 Modeling Issues 
The LS/NB model departs from common practice in taking survival times to be discrete. This 
approach does not primarily reflect an impulse to model the data as they are, although SEER-
Medicare survival times are in fact rounded to the nearest month. With the wide range of 
survival times, this is actually a fine rounding grid, and analyzing the data as though they are 
continuous should cause little bias.22 An advantage of assuming discreteness is that it simplifies 
calculation, as one can compute all needed quantities — probabilities, means, and likelihood 
terms — by direct summation. 
Because standard discrete distributions fit poorly to post-lead-time survival, we eschewed 
them in favor of flexible, easily estimated spline models on the logit hazard. Modeling survival 
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time in the Previous group is more challenging, because if one specifies both the lead time and 
the post–lead-time survival using nonparametric or overly flexible parametric forms, their 
convolution can be nonidentifiable. Therefore, for the lead-time distribution, we settled on the 2-
parameter NB, which is more flexible than the Poisson and geometric distributions but retains an 
easily computed mean function. Analysis under a range of alternative models showed substantial 
sensitivity of estimates of 𝐸(𝑇) and modest sensitivity of estimates of OR. Supporting our initial 
intuition, the NB appeared to offer a good fit when evaluated by the AIC. 
Our analysis is made possible by the availability of the No-Previous group — that is, a 
sample whose survival times are free of lead-time bias. Assuming that survival in the No-
Previous group is the same as post–lead-time survival in the Previous group, possibly up to an 
OR parameter, we can readily identify the lead-time distribution. An approach that we tried 
initially was to estimate a common 𝑆𝑁(𝑥) = 𝑆𝑃(𝑥) nonparametrically from the No-Previous data 
and solve for 𝑓𝑇(𝑡) by inverting the convolution equations (1). Unfortunately, the solution 
yielded probabilities outside [0, 1], even when we constrained the support of 𝑇 to include only 
the first few nonnegative integers. Thus, despite the large sample size, some smoothing is 
necessary. 
A key assumption is that 𝑇 and 𝑋𝑃 are independent. A plausible departure from this 
assumption is that the association is positive, in which case tumors that arise with shorter lead 
time are also more rapidly fatal.19 As both lead time and post–lead-time survival in the Previous 
group are latent, one cannot test this hypothesis robustly. In a sensitivity analysis, we 
demonstrated that failure to account for correlation could induce bias when the true correlation is 
moderate. One could reduce this bias by adjusting for potential confounders of the relationship 
between lead time and post–lead-time survival. 
 26 
 
We considered correction methods like those proposed by Duffy et al21 but found them to 
have several shortcomings: First, the adjustments to the observed 𝑧 values use only information 
on an assumed exponential distribution of 𝑇 and ignore the model for 𝑋𝑃; that is, they adjust 
using the incorrect conditioning set 𝑇 ≤ 𝑧 rather than 𝑇 + 𝑋𝑃 ≤ 𝑧. Second, the method requires 
that one possess estimates of the parameters of 𝑇 from previous data; such estimates may be 
available in special cases, but in general, they are elusive. And finally, even if one could perform 
the adjustments correctly by subtracting the conditional mean of 𝑇, the method would be 
analogous to single imputation of the predicted mean lead time and therefore would understate 
uncertainty. Our attempts to implement these analyses (not shown) demonstrated that adjustment 
formulas do not work as well as full estimation within the models from which they are derived. 
A multiple-imputation approach that involves taking repeated draws from the predictive 
distribution of the latent 𝑋𝑃 given (𝑧, 𝑑) would address this concern.23 
As indicated above, the survival advantage of the Previous group is only apparent for deaths 
from lung cancer, in an analysis that censors subjects at the time of death from other causes. 
Such an analysis implicitly assumes independence of times to death from cancer and other 
causes, a hypothesis whose validity is by no means certain and that one cannot test robustly. 
Moreover, because SEER cause-of-death data are not adjudicated, this outcome is subject to 
errors of misclassification. A possible enhancement of the method would be to jointly model lead 
time, mortality from cancer, and mortality from other causes, thereby creating valid estimates of 
cause-specific hazard functions. 
Assuming that the Previous and No-Previous survival curves are identical except for a lead-
time bias, one can estimate 𝐸[𝑇] by simply taking the difference between estimates of 𝐸[𝑍] and 
𝐸[𝑋𝑁], the first 2 columns in Table 1-3. Estimates computed in this way are similar to the model-
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based estimates from the sensitivity analysis with OR = 1.0 in Table 1-6, at least for stages III 
and IV. The fact that estimates of 𝐸[𝑇]  vary by end point suggests an inadequacy in the model, 
because the putative lead-time bias should be identical for survival end points measured from the 
same diagnosis time. Jointly modeling the 2 types of death would resolve this ambiguity. 
1.5.3 Clinical Implications 
Because the SEER-Medicare database contains only persons who are eligible for Medicare, 
we restricted our analysis to subjects aged 66 or older; thus, our findings may not be relevant to 
the entire lung cancer population. We note, however, that the median age at diagnosis of lung 
cancer is 70, and 69% of US lung cancer diagnoses occur at ages >65;24 therefore, our data 
represent the majority of US lung cancer patients. Moreover, we recently demonstrated that, 
among lung cancer patients in SEER (2009-2013), 8.6% of those <65 years and 18.7% of those 
≥65 years are survivors of a previous, non–lung cancer.25 Thus, our study, while limited to older 
adults, represents the majority of all lung cancer patients and of lung cancer patients who have 
survived a previous cancer. 
Our findings suggest that lead-time bias is one possible cause of the observed, modest, 
positive effect of a previous cancer diagnosis on lung cancer survival time. Other factors that 
underlie the observed differences are unknown but may include physiologic and health care 
delivery effects, misclassification, and residual confounding. Because SEER does not conduct 
active follow-up, it cannot provide validated data about metastatic disease occurring after initial 
cancer diagnosis. Nor does SEER measure smoking status, which is a potentially powerful 








The University of Texas Southwestern Medical Center Moncrief Cancer Institute has 
established a survivorship program to enhance the quality of life for cancer survivors, focusing 
on their mental and physical health. The program includes specialized exercise and nutrition 
training, as well as group and individual education and counseling. Benefits of participation in 
this program are unknown. We combined tumor registry and electronic medical record data for 
the safety-net healthcare system in Tarrant County, TX with participation data from the 
survivorship program. We identified patterns of participation through statistical clustering. We 
used regression models to measure the effect of participation on behaviors and on the frequency 
of Emergency Department (ED) visits. Among 467 program participants, we identified four 
clusters representing distinct patterns of participation. Our results demonstrated that participation 
in the survivorship program was associated with a 37% lower rate of ED visits (p < 0.0001). The 
study findings could further shape delivery of the survivorship services in our institution and 
similarly situated organizations across the country. In addition, these findings will provide 
insurers and policy makers with information to make evidence-based decisions regarding 
reimbursement for cancer survivorship programs. 
2.1 Introduction 
Cancer detection and treatment advances have led to rapid growth in the number of cancer 
survivors. An estimated 15.5 million survivors represented 4.8% of the United States population 
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in 2016 and projected to increase by 31% to 20.3 million by 2026.26 Data from the Surveillance, 
Epidemiology, and End Results (SEER) Program27 suggest about 67% of people diagnosed with 
cancer survive 5 years or more. Although cancer is more survivable than ever, many survivors 
become “lost in transition” once systematic care and treatment is finished.28 In addition, 
survivors often face devastating physical, psychosocial, and economic effects from the disease 
and treatment that affects quality of life. Thus, it has been proposed comprehensive survivorship 
programs can help cancer survivors address the likely physical, psychological, social and 
financial problems encountered in their next stage of life.29 
A major barrier to survivorship care is cost.30 The majority of cancer survivorship programs 
are associated with large cancer centers or academic medical centers and limited in scope 
because they are expensive and poorly reimbursed. Cancer survivors typically face the high 
treatment costs, lost work time and/or impairment in the ability to work31, and loss of health 
insurance. As a results, many are unable to afford the additional, unreimburseable costs for 
cancer survivorship services. 
Moncrief Cancer Institute (MCI), an affiliate of UT Southwestern Medical Center (UTSW), 
is a non-profit community-based cancer prevention and support center. MCI has established a 
survivorship program using a community-based model to provide patient-centered care. This 
survivorship program provides opportunity for cancer survivors to improve their health and 
quality of life by addressing any lingering medical and psychosocial effects of illness in addition 
to promoting healthy lifestyle changes. MCI offers cancer survivors multidisciplinary services 
regardless of diagnosis, stage, treatment provider, socioeconomic status, or insurance coverage. 
In this paper, we analyze sociodemographic and clinical characteristics of cancer survivors 
who took part in the MCI program. We use statistical clustering methods to identify common 
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patterns of service utilization. We further estimate the association of program participation with 
frequency of emergency department (ED) visits, to understand the potential impact of 
survivorship programs at the health system level.  
2.2 Materials and Methods 
 Study procedures 
This retrospective analysis uses three data sources:  The John Peter Smith Hospital (JPS) 
tumor registry database, JPS healthcare system electronic medical records (JPS EMR), and the 
UTSW-MCI Surviviorship database. JPS is a safety-net healthcare system providing care for 
low-income, under- and un-insured patients living in Tarrant County, TX. Subjects were patients 
18 years and older and diagnosed with cancer between January 1, 2005 and December 31, 2015, 
identified from the JPS tumor registry. We divided patients into two groups: The intervention 
group are participants who had one or more visits to the UTSW-MCI survivorship program from 
November 1, 2012 through December 31, 2016. The control group consisted of patients who did 
not participate in the cancer survivorship program during that period. 
After the groups were identified, a patient level database was created that contained: 1) 
patient sex, age, race/ethnicity, language, marital status, alcohol use, tobacco use, cancer case 
class, cancer type, cancer stage, cancer grade, cancer diagnosis year from the tumor registry, 2) 
ED visits from the EMR and 3) survivorship program services from the MCI delivery database. 
The survivorship program offered eleven different types of program services as follows: 
x RN Encounter - An Oncology Certified Nurse (OCN) conducts a physical needs 
assessment based on cancer treatment and health history, including cancer screening and 
surveillance adherence, creating a survivorship care plan where appropriate. 
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x SW Encounter - A licensed medical social worker (LMSW), completes a psycho-social 
evaluation to determine need for care coordination and/or financial assistance.  
x 1:1 Exercise session - An American College of Sports Medicine (ACSM) certified 
Cancer Exercise Trainer designs an individualized safe physical post-treatment activity 
plan for the participant after reviewing the medical history, exercise history, and fitness 
goals. The routine provides guidelines for improvement in areas like cardiovascular 
endurance, muscle strength and endurance, flexibility, range of motion, and balance. 
x Nutrition Counseling – A registered dietitian (RD) evaluates the participants’ dietary 
behaviors and needs to provide assistance with making nutritious foods and lifestyles 
choices, particularly when food security is an issue. 
x Midlevel Provider Encounter - Medical consultations provided by a Physician Assistant 
for the treatment of comorbid conditions, interval testing post treatment, etc. 
x Psychology Encounter - A psychologist consults with participants and their families to 
address psychosocial distress, anxiety and depression. 
x Genetic Counseling - A board certified genetic counselor (CGC) assesses the 
participant’s family and personal history along with any screening results, to identify the 
risk level for cancer and provides genetic testing where appropriate, along with guidance 
for early detection and prevention measures. 
x Group Exercise Session - A safe physical activity designed and coordinated for a group 
setting by an ACSM certified Cancer Exercise Trainer. 
x Support Group Session - Groups led by a licensed medical social worker (LMSW) to 
provide counseling for specific issues (e.g. smoking cessation, caregiving) or cancer type 
(prostate, brain, head-and-neck). 
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x Group Education – RD - A RD provides instruction on healthy food preparation and meal 
planning in a group setting.  
x Group Education – RN – Diagnosis specific education and survivorship care planning 
provided in a group setting by an OCN. 
Each service was designed to help cancer survivors to develop a healthy lifestyle, reduce the risk 
of recurrence or secondary cancers, and address psychological and social problems as a result of 
their disease and its treatment. All participants were strongly encouraged to attend 1 RN and 1 
SW visit; after which, they were encouraged to engage in program services aligning with the 
needs identified during the initial encounters.  
 Statistical analysis 
We first compared patient characteristics of program participants to all possible non-
participants and to the matched set of non-participant controls using descriptive statistics 
(number, percent) and chi-square statistics from univariate logistic model. 
For each type of program service, we estimated a random-effects, zero-inflated Poisson 
(ZIP) mixed model to predict the count of visits to that type of program service (Model 1). We 
had 11 models separately for 11 type of services and for each participant, 11 random effects were 
estimated correspondingly.  We then applied principal component analysis (PCA) to the 
standardized (subtracted by mean and divided by standard deviation) estimated random effects 
from ZIP models. We used the selected components obtained from PCA methods as input to a k-
















ln(𝜇𝑖𝑗) = 𝛼𝑗 + 𝑒𝑖𝑗 + ln⁡(𝑡𝑖𝑗) 
where = 1, 2, … , 𝑛 : participant ID; 
            𝑗 = 1, 2, … , 11 : service type indicator; 
           𝑦𝑖𝑗 : the number of visits of participant 𝑖 to service 𝑗; 
           𝑤𝑗 : the zero-inflation proportion for service 𝑗; 
          𝜇𝑖𝑗 : mean number of program visits; 
           𝛼𝑗: an intercept parameter; 
          𝑒𝑖𝑗: the random individual effect for participant i on type j service; 
          𝑡𝑖𝑗 : the offset representing the duration between the individual’s starting date of type 𝑗 
service and last observed program date of any type of service. Individual’s starting date is 
defined as follows: if individual 𝑖 participated in type 𝑗 service, his starting date is either his 
enrollment date or the very first observed program date of type 𝑗 service among all participants 
(overall first program date of type 𝑗 service ), whichever comes later;  if individual 𝑖 didn’t 
participate in type 𝑗 service, his starting date is his enrollment data if his last observed program 
date is before overall first program date of type 𝑗 service, otherwise his starting date is either his 
enrollment data or the overall first program date of type 𝑗 service, whichever comes later. 
To study the effect of sociodemographic and clinical factors on program participation, we 
fitted a multivariate logistic regression model that estimated the expected probability of 
participation, with all measured covariates. Given the considerable number of missing 
observations for alcohol use and tobacco use, we imputed missing values using logistic 
regression. To do so, we built a logistic regression with observed alcohol use as outcome and all 
other covariates except tobacco use as predictors. This model was then used to predict the 
missing alcohol use.  A similar method was used to impute tobacco use. Because patients can 
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have more than one primary reportable neoplasm over their lifetime, we describe characteristics 
of the patients’ most recent cancer. Sequence number reflects whether the selected tumor was the 
patient’s first or only tumor, or a second or higher-order tumor.33 Case class identifies the role of 
the reporting facility in the patient's diagnosis and treatment. Analytical cases are those 
diagnosed by or receiving part or all of the first course of treatment at the reporting facility; non-
analytical cases were diagnosed and received all of the first course of treatment at another 
facility.34 We used these propensity scores to match each program participant to 3 non-
participants, allowing us to estimate effects of program participation with minimal confounding 
bias. 
To study the effect of program participation on frequency of ED visits, we also applied the 
random-effects ZIP model to the dataset. We estimated two models. For the first (Model 2), we 
examined whether the count of ED visits differed by any program participation. We applied the 
model to the propensity score matched data, with count of ED visits as the outcome and 
participation status as the predictor. The participation status is always 0 for non-participants; for 
a participant, the status switches from 0 to 1 at the time of first participation in a program 
service. In this model, the participation status could affect whether the survivors has ED visits 
















) = 𝛼2 + 𝛽2𝑋𝑖 
where ⁡𝑖 = 1, 2,⋯ , 𝑛 : patient ID; 
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          𝑦𝑖 : the number of ED visits of patient 𝑖; 
          𝑤 : the zero-inflation proportion; 
         𝜇𝑖 : mean number of ED visits; 
           𝛼1: the intercept parameter to predict the mean number of ED visits; 
          𝛽1 : the fixed participation effect to predict the mean number of ED visits; 
         𝑋𝑖 : the participation status   ̶  Participants before-program and non-participants: 0; 
participants after-program: 1; 
          𝑒𝑖: the random individual effect; 
          𝑡𝑖 : the offset: for non-participants, the offset is the duration between the first and last 
recorded ED visit dates; for participants, there are two stages: before-program and after-program. 
In the before-program stage, the patients have not yet initiated participation in the survivorship 
program; the offset for this stage is the duration between the first ED visit date and the first 
survivorship program date.  In the after-program stage, the patients have started participating the 
program; the offset is the duration between the first program date and the last observed date, 
either the last program participation date or the last ED visit date, whichever comes later; 
           𝛼2: the intercept parameter to predict the zero-inflation proportion; 
           𝛽2 : the fixed participation effect to predict the zero-inflation proportion. 
 
For the second model (Model 3), we further examined the program effect on ED utilization 
by membership in the program participation clusters. We applied this model only to survivorship 
program participants. It took outcome as the count of ED visits and an indicator of cluster 














ln(𝜇𝑖) = 𝛼 + 𝛽1𝑋𝑖1 + 𝛽2𝑋𝑖2 + 𝛽3𝑋𝑖3 + 𝛽4𝑋𝑖4 + 𝑒𝑖 + ln⁡(𝑡𝑖) 
where = 1, 2,⋯ , 𝑛 : participant ID; 
           𝑦𝑖 : the number of ED visits of participant 𝑖; 
            𝑤 : the zero-inflation proportion; 
           𝜇𝑖 : the mean number of ED visits; 
            𝛼: the intercept parameter to predict the mean number of ED visits; 
           𝛽1, 𝛽2, 𝛽3, 𝛽4: the fixed effects of cluster 1-4 to predict the mean number of ED visits;  
          𝑋𝑖1, 𝑋𝑖2, 𝑋𝑖3, 𝑋𝑖4 : the cluster status indicator; 𝑋𝑖𝑗 = 1, if participants is in cluster⁡𝑗 ; 
otherwise, 𝑋𝑖𝑗 = 0, 𝑗 = 1, 2, 3, 4. 
          𝑒𝑖: the random individual effect; 
          𝑡𝑖 : before-program: the offset is the duration between the first ED visit date and the first 
survivorship program date; after-program: the offset is the duration between the first program 
date and the last observed date, either the last program participation date or the last ED visit date, 
whichever comes later. 
2.3 Results 
Among 8,435 cancer survivors, 467 (5.5%) participated in the survivorship program. The 
average age (interquartile range, IQR) is 51.9 (47-59) for participants and 54.8 (47-63) for non-
participants, additional characteristics by participation status are in Table 2-1. Cancer survivors 
who are female, younger, Hispanic or black, have quit smoking, and those with certain cancer 
types are significantly more likely to participate in the survivorship program (Table 2-1). We 
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then matched each participant to three non-participants based on the propensity score obtained 
from the multivariate logistic regression model. The matching balanced the covariates between 
the participation groups (p > 0.05 for all covariates after matching). All remaining analyses 
compared participants to matched non-participants. 
Table 2-1. Summary statistics of participants and non-participants 











Total  467 7968 1401   
Sex Female 331(70.9) 4296(53.9) 976(69.7) <0.001 0.62 
 Male 136(29.1) 3672(46.1) 425(30.3)   
Age 18-39 55(11.8) 996(12.5) 177(12.6) <0.001 0.66 
 40-54 213(45.6) 2576(32.3) 593(42.3)   
 55-64 167(35.8) 2887(36.2) 525(37.5)   
 65+ 32(6.8) 1509(18.9) 106(7.6)   
Race Hispanic 171(36.6) 1794(22.5) 498(35.5) <0.001 0.98 
 Non-Hisp White 134(28.7) 3740(46.9) 406(29.0)   
 Non-Hisp Black 149(31.9) 1962(24.6) 456(32.5)   
 Non-Hisp Other 13(2.8) 472(5.9) 41(2.9)   
Language English 6663(83.6) 1085(77.4) 358(76.6) <0.001 0.88 
 Spanish 97(20.8) 916(11.5) 277(19.8)   
 Other 12(2.6) 389(4.9) 39(2.8)   
Marital 
Status 
Single 2959(37.1) 499(35.6) 167(35.8) 0.044 0.95 
 Married 174(37.2) 2818(35.4) 530(37.8)   
 Separated 22(4.7) 213(2.7) 63(4.5)   
 Divorced 71(15.2) 1166(14.6) 224(16.0)   
 Widow 24(5.1) 587(7.4) 66(4.7)   
 Unknown 9(1.9) 225(2.8) 19(1.4)   
Alcohol Current 89(19.0) 1875(23.5) 272(19.4) <0.001 0.99 
 Previous 9(1.9) 504(6.3) 27(1.9)   
 Never 369(79.0) 5589(70.1) 1102(78.6)   
Tobacco Current 115(24.6) 2928(36.7) 351(25.0) <0.001 0.81 
 Previous 80(17.1) 1470(18.4) 256(18.3)   
 Never 272(58.2) 3570(44.8) 794(56.7)   
Sequence 
number 
First or only cancer 429(91.9) 6815(85.5) 1275(91.0) <0.001 0.57 
 Second or higher order 
cancer 
38(8.1) 1153(14.5) 126(9.0)   
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Case class Analytic 417(89.3) 6615(83.0) 1246(88.9) <0.001 0.83 
 Non-analytic 50(10.7) 1353(17.0) 155(11.1)   
Cancer type Breast 143(30.6) 970(12.2) 401(28.6) <0.001 1.0 
 Colon and Rectum 42(9.0) 759(9.5) 122(8.7)   
 Corpus and Uterus 29(6.2) 253(3.2) 90(6.4)   
 Kidney and Renal 24(5.1) 301(3.8) 73(5.2)   
 Leukemia 10(2.1) 95(1.2) 29(2.1)   
 Liver 10(2.1) 326(4.1) 28(2.0)   
 Lung and Bronchus 28(6.0) 994(12.5) 87(6.2)   
 Lymphoma-NHL 20(4.3) 208(2.6) 62(4.4)   
 Myeloma 11(2.4) 119(1.5) 31(2.2)   
 Oral Cavity Pharynx 10(2.1) 343(4.3) 32(2.3)   
 Prostate 30(6.4) 376(4.7) 106(7.6)   
 Vagina, Vulva, Ovary 14(3.0) 222(2.8) 40(2.8)   
 Other 96(20.6) 3002(37.7) 300(21.4)   
Stage In situ 31(6.6) 481(6.0) 91(6.5) <0.001 0.97 
 Localized 167(35.8) 2315(29.0) 525(37.5)   
 Regional 135(28.9) 1684(21.1) 392(28.0)   
 Distant 93(19.9) 2144(26.9) 277(19.8)   
 Other 41(8.8) 1344(16.9) 116(8.3)   
Grade Poor 101(21.6) 1265(15.9) 298(21.3) <0.001 0.97 
 Moderate 137(29.3) 1775(22.3) 409(29.2)   
 Well 60(12.8) 731(9.2) 192(13.7)   




Continuous    <0.001 0.85 
* Two-sided P value calculated from univariate logistic model by Wald Chi-squared test;  aComparing participants 
to all non-participants; bComparing participants to nonparticipants (1:3) matched on propensity scores of all 
measured covariates.  
 
We investigated the participation pattern of patients according to their service type and 
frequency. We applied PCA to the estimated patient random effects from the ZIP model. The 
first four components explained roughly 80% of the variability in types and frequency of 
program services received, so we applied k-means clustering on these components, identifying 
four clusters as the optimal solution. The clusters —of sizes 93 (20%), 130 (28%), 198 (42%), 
and 46(10%) — appear in Figure 2-1. We calculated the proportion of participants attending the 
different type of service as well as the average number of visits across clusters (Figure 2-2). 
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Among all participants, the approximate proportion of participation in the 1:1 exercise is 50%, 
20% for different group-activity sessions and psychology encounters, 45% for nutrition 
counseling, over 80% for RN or SW encounter, and less than 5% in mid-level provider encounter 
and genetic counseling. The average number of visits of any type of service is 10.1, respectively 
5 for 1:1 exercise session, 1 for nutrition counseling, psychology encounter, RN or SW 
encounter, and less than 1 for the other types of services. On average, participants spent 161 days 
on the program.  
The clustering identifies different participation patterns: Patients in Cluster 1 received 
services related to exercise and diet lifestyle behaviors; 97% of the participants in Cluster 1 
participated in a 1:1 exercise session where the average session count exceded 11; 86% 
participated in nutrition counseling with an average participation count of 2.6. Cluster 2 engaged 
in multiple types of sessions: 61% participated in 1:1 exercise with an average visit count of 7.4; 
55% of them attended nutritional counseling, and around 40% participated in group-activity 
sessions. Cluster 3 opted for sessions involving interaction with nurses (97%) and social workers 
(90%); the frequencies for other types of service were all less than average. Cluster 4 gravitated 
toward group-activity sessions; rather than individual RN or SW encounters (around 25%), they 
preferred group-activity sessions (over 80% in all different group-activity session). The average 
number of visits of any type of service is 19.7, 15.3, 3.3 and 5.5 for Cluster 1, 2, 3, 4 respectively 




Figure 2-1. k-means clusters visualized in principal components coordinates. (PC1-PC4: the first 
four principal components) 
Next, we analyzed ED visits. Most survivors (85%) had no ED visits, including non-
participants (85%), participants before program (84%) and participants after the program (86%). 
Corresponding to non-participants, participants before the program and participants after 
program, the proportion of survivors who had 1 to 4 ED visits is 9.3%, 11.9% and 10.1%; the 
proportion of survivors who had more than 4 ED visits is 4.7%, 3.9% and 3.8%, respectively.  
We used the mixed ZIP model to examine the impact of the survivorship program on ED 
visits. We first estimated the effect of any program participation. The ratio of ED counts of 
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participants in the program to that of participants before the program and non-participants was 
0.63 (95% CI: 0.48 – 0.81), which means participation was associated with a 37% reduction in 
the number of ED visits (Figure 2-3, left panel). These models kept the zero-inflation proportion 
the same regardless of participation status; allowing it to differ by participation status gave 
similar results (not shown). We then examined, among participants, whether cluster membership 
had an effect on ED visits. The number of ED visits after program to that before program is 0.44 
(95% CI: 0.28 – 0.72), 0.51 (95% CI: 0.36 – 0.74), 1.26 (95% CI: 0.88 – 1.82) and 0.88 (95% CI: 
0.48 – 1.59) respectively for Clusters 1, 2, 3 and 4 (Figure 2-3, right panel). These results 
demonstrate that those who intensively participated in 1:1 exercise and nutrition counseling 
sessions (Cluster 1), as well as those who participated in a multiple, mixed types of  sessions 





Figure 2-2. Participation in different type of survivorship services by cluster type. Panel A shows 








Figure 2-3. Effect of participation in the survivorship program on ratio (the number of ED visits 
in the intervention group to that in the reference group) of emergency department (ED) visits. 
Panel A shows the effect of participants in the program vs. participants before program and 
matched non-participants (reference group). Panel B shows the effect of different clusters of 
participation among participants only, comparing the ratio of ED visits after program 
participation to the ratio before program participation (reference group). A ratio of 1.0 indicates 
that the number of ED visits in the intervention group is the same as the reference group. A ratio 
less than 1.0 demonstrates fewer ED visits in the intervention vs. reference group. 
 
2.4 Discussion 
In 1986, the National Coalition for Cancer Survivorship (NCCS) was founded to establish 
programs to help cancer survivors deal with the long-term effects of their disease and its 
treatment.35 The Institute of Medicine (IOM) has provided guidance for the implementation of 
comprehensive cancer survivorship care plans.28,29,36 Researchers have studied cancer 
survivorship from a range of perspectives.37 Wattchow et al.38 found that colon cancer patients 
with follow-up led by surgeons or general practitioners experience similar outcomes regarding 
quality of life, anxiety and depression, and patient satisfaction. Knowles et al.39 demonstrated 
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that a nurse-led model for colorectal cancer survivors was safe, efficient and cost-effective. In a 
randomized trial, Grunfeld et al.40 found that receiving a survivorship care plan (SCP) did not 
improve breast cancer survivors' distress. Nevertheless, much remains unknown, and there is a 
pressing need for evidence-based guidance regarding the types and frequency of survivorship 
services, along with which models of survivorship care improve patient outcomes. 
Prior studies investigated the effects of survivorship program participation and number of 
cancer follow-up providers on the occurrence of ED visits.41,42 To our knowledge, there has been 
no study classifying survivorship program participants according to their patterns of use of the 
different types of service, not to mention analyzing the association between these patterns and 
the frequency of outcomes such as ED visits. Our study also goes beyond prior studies by 
focusing on low-income, under- and uninsured patients, including multiple disease sites, and by 
using propensity scores to account for differences between participants and non-participants.  
We demonstrated participation in the MCI survivorship program is significantly associated 
with lower rates of ED visits. The exact mechanisms for this effect are not known.  It is possible 
the services provided may reduce ED visits by lessening the severity of medical conditions 
needing urgent care.  It is also possible participants are seeking advice or care from program 
personnel before their condition worsens to the point where an ED visit is necessary. Several 
studies have shown the frequency of ED visits among cancer survivors exceed those of the 
general population.43-45 Moreover, Panattoni et al.46 found 49.8% of ED visits in a commercially 
insured oncology population had a potentially preventable cancer-related diagnosis with a related 
median reimbursement of $1,029 per ED visit. Our findings suggest a survivorship program can 
provide an opportunity to prevent avoidable ED visits. The cost-effectiveness of this approach is 
unknown and deserves further study47. 
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We also demonstrated distinct utilization patterns among survivors. We identified four 
clusters, perhaps reflecting differences in patient interests or preferences for services, or perhaps 
the availability and accessibility of different services. Participants in two of the four clusters had 
reductions in ED visit rates by roughly half after beginning participation. This suggests the most 
effective program components may be associated with these clusters: 1:1 exercise sessions, 
nutrition sessions, etc. 
Our study had several strengths. Linking the three data sources allowed us to analyze 
patterns and effectiveness of cancer survivorship program use, to characterize and classify 
survivorship program usage, and to evaluate the effectiveness of program participation using ED 
visits.  Our study also has several limitations. Because survivorship programs vary across 
institutions, our results may not be relevant to different programs. Also, ED visits were captured 
within a single healthcare system and survivors could have been seen elsewhere.  However, 
because this population is low-income, under- or uninsured, and received all or most of their 
cancer diagnosis and treatment at JPS, and because JPS is the only integrated safety-net system 
in the county, this seems like an unlikely scenario. In addition, as an observational study, 
unobserved confounding may bias our results.    
In conclusion, our study provides useful information for health care providers and cancer 
centers to guide development, implementation, and outcome evaluations for future cancer 
survivorship programs. These findings also provide evidence for insurers and payors to design 
benefits, policies, and reimbursement mechanisms to facilitate coverage. Future studies will 
evaluate the effect of survivorship program participation on other health service utilization, like 







Among newly diagnosed cancer patients, those who survived a previous cancer have been 
reported to live longer than those with no previous cancer.   Possible explanations for this 
phenomenon are lead-time bias and true biological effects. We propose a discrete competing-risk 
model with adjustment for lead-time bias to describe the effect of a previous, non-lung cancer 
diagnosis on the cause-specific survival of patients with lung cancer.  We assume that the 
observed survival for patients with previous cancer is the sum of lead time and post-lead-time 
survival.  We describe the former with a negative binomial distribution, and the latter with a 
discrete cause-specific hazard, modeled as the inverse logit of a spline function on time.  We 
assume that post-lead-time survival in patients with no previous cancer differs from that in 
cancer survivors by an odds ratio parameter. We applied our model to propensity score-matched 
linked SEER–Medicare data.  We estimate mean lead time to be less than one month at all lung 
cancer stages; the effect of including lead time on estimates of group differences is modest.  
Patients with a previous cancer had significantly lower hazard for lung-cancer death and non-
cancer death than patients without a previous cancer. Under a competing-risk model, lead-time 
bias is modest, and does not explain differentials in cause-specific survival between lung cancer 
patients with and without previous cancer.  Patients with previous cancer have reduced hazards 




The number of cancer survivors is growing rapidly, leaving more of them at risk of a second 
primary cancer.1,25  Lung and bronchus cancers are the leading cause of cancer-related death in 
the US.1  Roughly 20% of patients aged 65 and over with a new diagnosis of a respiratory cancer 
have experienced a previous cancer of some other kind.25  
Several studies have investigated the impact of a previous cancer diagnosis on survival in 
lung cancer and other diseases.  Curiously, among lung cancer patients older than 65 years, those 
with a history of a previous cancer had similar or better all-cause survival, depending on the 
stage of lung cancer.  Across all stages of lung cancer, those with a previous cancer had on 
average longer lung cancer-specific survival.2-4 
A possible explanation for this observation is lead-time bias, which occurs when 
surveillance advances the date of diagnosis of a disease.   In cancer, we typically define lead time 
to be the difference between the date of diagnosis when observed through screening and the 
(latent) date at which the diagnosis would have occurred without screening.48-51  For lung cancer 
patients with a history of cancer, it is possible that a lead time could arise through enhanced 
surveillance.  That is, cancer survivors who harbor an as yet undiagnosed lung tumor could have 
that tumor discovered early through additional testing they undergo as follow-up to their 
previous cancer.52  Lead-time bias occurs when the diagnosis date is advanced such that mean 
survival time appears to be longer, even when no survival advantage exists. 
In a previous article, we proposed a statistical model for lead-time bias and survivorship, 
and observed that even after accounting for lead time, time to death from lung cancer was 
significantly longer for patients with a previous cancer diagnosis.52  Our method of analysis did 
not, however, account for competing risks of death, in that it treated all non-lung cancer deaths 
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as censoring events.  This approach has several weaknesses:  First, it implicitly assumes that the 
latent times of death from each cause are statistically independent, an assumption that is 
impossible to evaluate robustly.53  Indeed, it is more plausible that latent death times are 
positively correlated, reflecting different levels of frailty, in which case estimates of survival 
assuming independence are biased upward.54  Second, the survival curve assuming latent, 
independent death times estimates the survival curve that would occur if we could eliminate the 
competing causes of death.  This is problematic because there is no reason to believe that 
eliminating non-lung cancer causes of death would leave lung cancer death times unaffected.  
Thus, not only the validity but the relevance of these estimates is questionable.  Finally, we note 
that our estimates of mean lead time differed by survival outcome (death from any cause vs. 
death from lung cancer), possibly reflecting these biases and suggesting the need for a 
comprehensive approach to modeling lead time and cause-specific survival.52 
As early as 1957, Cornfield55 observed that the existence of competing risks complicates the 
interpretation of cause-specific mortality rates.  Prentice et al.56 proposed to study the 
interrelations among competing causes of failure through cause-specific hazard functions, which 
one can estimate without the need for unverifiable assumptions.  Later, Fine and Gray18 proposed 
a proportional hazards model to estimate the cumulative incidence of a competing risk.  Yet 
Austin and Fine57 observed that despite these advances, fewer than 20% of randomized trials in 
which competing risks data arise present a competing-risks analysis. 
Although it is typical to treat survival data as though they are continuous, in fact they are, 
like all data, essentially discrete.  With Surveillance, Epidemiology, & End Results (SEER)-
Medicare cancer survival data, for example, diagnosis and survival dates are only accurate to the 
nearest month.  Thus, many such observations may have equal, or “tied”, survival times, a 
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circumstance that complicates the analysis of data that we assume to be continuous.  Tutz58 
proposed a discrete competing-risks model that one can estimate in the framework of the 
generalized linear model.  Ambrogi et al.59 proposed to estimate cumulative incidences through 
multinomial logit regression analysis of discrete cause-specific hazards. 
In this article, we propose a discrete competing-risk model to estimate the cause-specific 
hazard for lung cancer patients with a previous diagnosis of cancer.  We adjust our results by 
assuming that lung cancer diagnosis time in survivors of a previous cancer is potentially subject 
to a lead-time bias.  We model the cause-specific hazards as inverse logits of linear splines on 
time, assuming that a previous cancer diagnosis affects the cause-specific hazard through an odds 
ratio factor.  We assume that the lead time follows a negative binomial distribution and is 
independent of the latent survival time.  We estimate the mean lead time, the odds ratios of the 
cause-specific hazards, and the cause-specific cumulative incidence rates by maximum 
likelihood, applying our method to linked SEER-Medicare data on lung cancer patients. 
3.2 Methods 
 Data Source 
We used linked 1992–2011 National Cancer Institute SEER program files and 1991–2013 
Medicare claims files from the Centers for Medicare & Medicaid Services.  The Institutional 
Review Board of the University of Texas Southwestern Medical Center approved our study. 
 Study Population 
We included patients older than 65 years with primary lung cancer diagnosed between 2000 
and 2011.  All patients had full coverage of Medicare Parts A and B from 1 year before to 1 year 
after the lung cancer diagnosis.  We included only patients with either non–small cell (NSCLC) 
or small cell (SCLC) lung cancer histology.  To ensure complete claims data, we excluded 
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patients who participated in health maintenance organizations and those with only autopsy or 
death certificate records.  We omitted patients with incomplete diagnosis or death dates or 
discrepancies in SEER and Medicare birth dates of a year or more.  We also excluded those who 
developed another cancer after the index lung cancer. 
We divided the patients into two groups:  Those with a history of cancer (the Previous group) 
and those without (the No-Previous group).  The Previous group included those who had only 
one previous, invasive, primary cancer that was not a lung cancer.  We stratified patients by 
American Joint Committee on Cancer lung cancer stage, grouping them into stages I&II, III, and 
IV, and excluding the heterogeneous “unstaged” stratum.  
 Measures 
We assumed three possible competing causes of death:  The previous cancer (possible for 
the Previous group only), the index lung cancer, and non-cancer causes.  We measured survival 
as the interval in months between the lung-cancer diagnosis and the date of death derived from 
SEER.  
To reduce confounding of previous cancer status with other potential correlates of mortality, 
we created a set of patients in the No-Previous group who were matched to the Previous group 
members.  We matched on a propensity score that predicted previous cancer status from 
available potential confounders in the SEER-Medicare database:  Age, sex (F,M), race/ethnicity 
(white, black, Hispanic, other), marital status (married, separated/divorced/widowed, single, 
unknown), histology (SCLC, NSCLC-adenocarcinoma, NSCLC-squamous, NSCLC-other), 
Charlson comorbidity score (0, 1, 2+, not available), Medicaid status (Y, N), and lung cancer 




 Statistical Analysis 
We propose a discrete competing-risk model to describe the cause-specific hazards in the two 
groups defined by prior cancer status.  We assume that there is a standard survival measure — 
the time from clinical diagnosis to death — that we denote post-lead-time survival and label 𝑋𝑁 
for subjects in the No-Previous group and XP for subjects in the Previous group.  Because there 
is, by definition, no possibility of lead-time bias in the No-Previous group, we observe XN 
directly.  In the Previous group, the observed survival is the sum of two independent 
components:  The notional post-lead-time survival XP and a random lead time T≥0 that is a 
consequence of additional surveillance that patients undergo as a result of the previous cancer.  
We see neither XP nor T directly; rather we observe their sum, which we denote Z=XP+T. 
The cause-specific hazard for cause r in the No-Previous group is defined as  ℎ𝑁𝑟(𝑥) =
Pr⁡(𝑋 = 𝑥, 𝑅 = 𝑟|𝑋 ≥ 𝑥). We model it with a linear spline on the logit scale: 
ℎ𝑁𝑟(𝑥) =
exp⁡[𝜂𝑁𝑟(𝑥)]









where mr is the number of knots; βjr, j=0,…,mr are the spline coefficients;  0 < 𝑘𝑟1 < ⋯ < 𝑘𝑟𝑚𝑟 
are the spline knots; and (𝑢)+ = max⁡(0, 𝑢).  We model the cause-specific hazard in the Previous 
group as 𝜂𝑃𝑟(𝑥) = 𝜂𝑁𝑟(𝑥) + γ𝑟; with this specification, OR𝑟 = exp⁡(γ𝑟) is the odds ratio of 
hazards comparing the Previous to the No-Previous group.  The overall hazard at time x in the 
No-Previous group is  ℎ𝑁(𝑥) = ∑ ℎ𝑁𝑟(𝑥)𝑅𝑟=1 ; the overall survival function is 𝑆𝑁(𝑥) =
Pr[𝑋𝑁 ≥ 𝑥] = ∏ [1 − ℎ𝑁(𝑗)]𝑗<𝑥 ; the cause-specific probability mass function is 𝑓𝑁𝑟(𝑥) =
ℎ𝑁𝑟(𝑥)𝑆𝑁(𝑥); and the cumulative incidence rate is 𝐹𝑁𝑟(𝑥) = ∑ 𝑓𝑁𝑟(𝑗)𝑗<𝑥 . 
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We calculate the probability mass function of the latent  𝑋𝑃 similarly.  To derive a 
distribution for Z, the observable time from diagnosis to death in the Previous group, we first 
assume that lead time 𝑇 follows the negative binomial distribution  𝑇~𝑁𝐵(𝜌, 𝜎), with 
probability mass function parameterized as 𝑓𝑇(𝑡; 𝜌, 𝜎) =
Γ(𝑡+𝜌)
Γ(𝜌)Γ(𝑡+1)
𝜎𝜌(1 − 𝜎)𝑡 for ρ>0 and 
0<σ≤1. Then the probability mass function of 𝑍 is the convolution of the densities of 𝑋𝑃 and 𝑇:  
𝑓𝑍𝑟(𝑧) = ∑ 𝑓𝑇(𝑡)𝑓𝑃𝑟(𝑧 − 𝑡)
𝑧
𝑡=0 . The cumulative incidence rate is therefore 𝐹𝑍𝑟(𝑧) = ∑ 𝑓𝑍𝑟(𝑗)𝑗<𝑧 , 
and the overall survival is 𝑆𝑍(𝑧) = 1 − ∑ 𝐹𝑍𝑟(𝑧)𝑅𝑟=1 . 
The loglikelihood for the matched dataset is 






) ln 𝑆𝑁(𝑥𝑖; 𝛽) ⁡]
𝑛𝑁
𝑖=1










where 𝑛𝑁 and 𝑛𝑃 are the numbers of patients in No-Previous and Previous groups, respectively; 
and 𝑑𝑖𝑁𝑟 and 𝑑𝑖𝑃𝑟 are indicators of whether patient 𝑖 died from cause 𝑟 in the No-Previous group 
and Previous group, respectively. 
We choose the spline knot locations by lasso variable selection.  We assume for each cause 
of death that the knots are the same in the Previous and No-Previous groups.  For lung-cancer 
death and other-cause death, we identify knots using data from the No-Previous group only.  For 
previous-cancer death, we find knots using data from the Previous group only.  Initially, we set 
knots at every fifth centile of the empirical distribution function of the survival data.  Using 
Equation (2), we fit the linear spline on the empirical net hazard, using lasso variable selection to 
choose at most another two knots besides 1 and 5th centile. 
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We estimate the model parameters by using generic optimization functions in the R statistical 
language.17  Having obtained maximum likelihood estimates of the parameters, we calculate 
estimates and confidence intervals for the odds ratios of the cause-specific mortality hazards, the 
mean lead time, and the cumulative incidence rate (CIR) for each event cause. The Online 
Supplement provides additional details. 
We conducted a range of sensitivity analyses:  The basic model assumes three causes of 
death:  Lung cancer, prior cancer, and other.  We also assumed a two-cause model in which we 
grouped together the prior cancer and other causes as a single cause of death.  To examine the 
impact of lead-time bias in the two-cause model, we estimated the odds ratios assuming that 
there was no lead-time bias. 
3.3 Results 
Among 173,635 eligible lung cancer patients, 42,994 (24.8%) were stage I&II; 50,084 
(28.8%) were stage III; and 80,557 (46.4%) were stage IV.  The proportions of lung cancer 
patients who had only one previous cancer were 15.3%, 12.5% and 12.0% for stages I&II, III, 
and IV, respectively.  Before matching, previous cancer prevalence differed across measured 
sociodemographic and clinical covariates; it was higher (P < 0.0001, Tables 3-1, S1, S2) in lung 
cancer patients who were older, male and without Medicaid.  A 1:1 propensity score matching 
eliminated these imbalances.  The remaining analyses use this matched dataset.  
Table 3-2 displays proportions of patients according to cause of death and stage.  Combining 
the Previous and No-Previous groups, the proportion who died of any cause increased as stage 
increased:  65.9%, 91.6%, and 97.1% for stages I&II, III, and IV, respectively.   For death from 
lung cancer the trend was similar:  39.0%, 71.6%, and 79.0% for stages I&II, III, and IV, 
respectively.  As more patients died of lung cancer in the higher stages, the proportion who died 
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from non-cancer causes declined, 21.1%, 14.2%, and 10.6% for stages I&II, III, and IV, 
respectively.   The proportions of overall, lung-cancer, and non-cancer deaths were all higher in 
the No-Previous group.  In the Previous group, the proportion of patients who died from the 
previous cancer also increased as lung cancer stage increased:  11.5%, 11.6%, and 14.9% for 
stages I&II, III, and IV, respectively. 
We computed estimates of the model parameters using the matched data.  Figure 3-1 shows 
estimated CIRs from the three-cause model.  It is clear that as stage advanced, the CIR for lung-
cancer death (dashed line) increased, while the CIR for non-cancer death (dot dashed line) 
decreased.  The No-Previous group (black lines) had higher CIR for both lung-cancer death and 
non-cancer death, compared to the Previous group (red lines).  For the Previous group, in stage 
I&II, the CIR for previous-cancer death (dotted line) is lower than that for non-cancer death; in 
stage III, their difference decreased; in stage IV, the order is reversed as CIR for previous-cancer 
death is higher than non-cancer death.  For the No-Previous group, the CIR for previous-cancer 
death is defined to be 0.  We calculated the CIR for death from any cause by summing the cause-
specific CIRs.  In stage I&II and stage III, the CIR of overall death (solid line) for the Previous 
group is higher than that for the No-Previous group.  In stage IV, the CIR of overall death for the 
Previous group is slightly less than that for the No-Previous group. 
 
Table 3-1. Characteristics of patients with stage I&II lung cancer. 
 n (%) P value 
 Previous No-Previous Matched No-Previous Unmatched Matched 
Total (n) 6594 36400 6594   
Age    <0.0001 0.88 
<75 2811 (42.6) 17491 (48.1) 2785 (42.4)   
75-85 3093 (46.9) 15766 (43.3) 3107 (47.1)   
≥85 690 (10.5) 3143 (8.6) 702 (10.6)   
Sex    <0.0001 0.17 
Female 2799 (42.4) 18220 (50.1) 2877 (43.6)   
Male 3795 (57.6) 18180 (49.9) 3717 (56.4)   
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Race    0.052 0.99 
White 5839 (88.6) 32006 (87.9) 5848 (88.7)   
Black 472 (7.2) 2541 (7.0) 468 (7.1)   
Hispanic 50 (0.8) 341 (0.9) 48 (0.7)   
Other 233 (3.5) 1512 (4.2) 230 (3.5)   
Marital Status    0.00032 0.77 
Married 3635 (55.1) 19015 (52.2) 3587 (54.4)   
Sep/div/wid 2324 (35.2) 13655 (37.5) 2382 (36.1)   
Single 416 (6.3) 2456 (6.7) 409 (6.3)   
Unknown 219 (3.3) 1274 (3.5) 216 (3.3)   
Histology    <0.0001 0.98 
Adenocarcinoma 3294 (50.0) 16394 (45.0) 3302 (50.1)   
Squamous 1927 (29.2) 11363 (31.2) 1911 (29.0)   
Small cell 230 (3.5) 1369 (3.8) 237 (3.6)   
NSCLS/other 1143 (17.3) 7274 (20.0) 1144 (17.3)   
Charlson Score    0.00083 0.72 
0 2490 (37.8) 13047 (35.8) 2465 (37.4)   
1 2026 (30.7) 11494 (31.6) 2058 (31.2)   
2+ 1895 (28.7) 10570 (29.0) 1906 (28.9)   
Not available 183 (2.8) 1289 (3.5) 165 (2.5)   
Medicaid    <0.0001 1.0 
Yes 851 (12.9) 6151 (16.9) 851 (12.9)   
No 5743 (87.1) 30249 (83.1) 5743 (87.1)   
Lung cancer 
treatment    <0.0001 0.86 
Surgery only 2507 (38.0) 15464 (42.5) 2518 (38.2)   
Chemo only 191 (2.9) 857 (2.4) 195 (3.0)   
Radiation only 1041 (15.8) 5261 (14.5) 1072 (16.3)   
≥2 treatments 1421 (21.5) 6980 (19.2) 1374 (20.8)   
No 
surg/chemo/rad 1434 (21.7) 7838 (21.5) 1435 (21.8)   
* Characteristics of patients with stage III and IV lung cancer appear in Tables S1 and S2. 
Table 3-2. Mortality fraction by lung cancer stage and cause of death. 
 Deaths by cause (%) 
Stage Group Patients Overall Lung cancer Non-cancer Previous cancer 
I&II 
Total 13188 8697 (65.9) 5150 (39.0) 2790 (21.1)  
No-Previous 6594 4417 (67.0) 2824 (42.8) 1593 (24.2) -- 
Previous 6594 4280 (64.9) 2326 (35.3) 1197 (18.2) 757 (11.5) 
III 
Total 12500 11450 (91.6) 8955 (71.6) 1773 (14.2)  
No-Previous 6250 5761 (92.2) 4746 (75.9) 1015 (16.2) -- 
Previous 6250 5689 (91.0) 4209 (67.3) 758 (12.1) 722 (11.6) 
IV 
Total 19430 18864 (97.1) 15354 (79.0) 2058 (10.6)  
No-Previous 9715 9472 (97.5) 8153 (83.9) 1319 (13.6) -- 
Previous 9715 9392 (96.7) 7201 (74.1) 739 (7.6) 1452 (14.9) 
 
Table 3-3 presents estimates of the mean lead time and the odds ratios of the cause-specific 
mortality hazards comparing the Previous group to the No-Previous group; we omit the OR for 
risk of death from previous cancer, which is by definition infinity. The estimated mean lead time 
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is less than 1 month: 0.53, 0.96, 0.48 months for stages I&II, III and IV respectively. It is 
interesting that the longest lead time is found in stage III, possibly because by the time stage I&II 
lung cancer becomes clinically detectable, it has already progressed to stage III.60 After 
adjustment for lead-time bias, the odds ratios are significantly less than 1 for lung-cancer death 
(ORl) and non-cancer death (ORnc).  This suggests that patients in the Previous group are 
relatively resistant to mortality from the subsequent lung cancer and to non-cancer causes, 
experiencing their greatest risk of death from previous tumors. Comparing the top and bottom 
panels of the table, it is apparent that estimated cause-specific odds ratios are robust to inclusion 
of lead time in the model. 
The estimated cumulative incidence rate, mean lead time and odds ratios for the two-cause 
data appear in Figure S1 and Table S3 in the Online Supplement.  In the two-cause data, 
estimates of mean lead time are modest and are similar to those in the three-cause data, as are 
values of ORl.   Combining previous-cancer and non-cancer death, odds ratios for other-cause 
death for the previous group versus non-previous group are significantly larger than one at all 
stages of lung cancer. This suggests that the competing risk from a previous cancer accounted for 




Figure 3-1. Cumulative incidence rate of death by stage and cause of death in the three-cause 
data for lung cancer patients with and without previous cancer. 
 
Table 3-3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the 
three-cause competing risk data. 
Lung cancer stage Mean lead time (95% CI) 
Lung cancer mortality 
ORl (95% CI) 
Non-cancer mortality 
ORnc (95% CI) 
 Assuming lead time 
I&II 0.53 (0.35, 0.72) 0.89 (0.86, 0.93) 0.89 (0.84, 0.94) 
III 0.96 (0.40, 1.53) 0.95 (0.91, 0.99) 0.83 (0.77, 0.89) 
IV 0.48 (0.03, 0.94) 0.88 (0.83, 0.92) 0.56 (0.51, 0.60) 
 Assuming no lead time 
I&II 0 0.88 (0.85, 0.92) 0.86 (0.82, 0.91) 
III 0 0.89 (0.87, 0.92) 0.84 (0.78, 0.89) 
IV 0 0.82 (0.80, 0.84) 0.66 (0.62, 0.70) 
ORl:  Odds ratio of the lung cancer mortality hazard of the Previous group relative to the No-Previous group.   
ORnc:  Odds ratio of the non-cancer mortality hazard of the Previous group relative to the No-Previous group. 
 
3.4 Discussion 
Applying our flexible, discrete-data competing-risk model to SEER-Medicare lung cancer 
data, we observed that estimated mean lead times are modest — less than one month in all 
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stages.  Regardless of adjustment for lead-time bias, the results in the three-cause data 
demonstrated that the hazards of both lung cancer death and non-cancer death are moderately 
less among patients with previous cancer compared to those with no previous cancer.  The two-
cause data further revealed that the competing risk of other causes accounted for the reduction of 
hazard of lung-cancer death.  Failure to adjust for lead-time bias results in modest 
underestimation of odds ratios, but as the mean lead time is small, so is the effect of estimating it 
on the OR parameters. 
The estimates of mean lead time differ from those in our previous analysis,52 which ignored 
the competing-risks aspect of the data.  Our earlier estimates of the mean lead time for lung 
cancer survival were 11.3, 1.1, and 0.3 months for stages I&II, III and IV, respectively, whereas 
under the three-cause model the corresponding estimates are 0.53, 0.96 and 0.48 months.   We 
conjecture that these discrepancies reflect a bias from ignoring competing risks.  The largest 
discrepancy is in stage I&II, where the percent of censoring from competing risks is highest, and 
therefore there is the greatest opportunity for bias.   Another possible explanation is that in the 
data set for our competing-risks analysis we excluded patients with multiple previous tumors and 
those who developed a second tumor after the index lung cancer.  These exclusions were 
necessary to ensure the accuracy of measuring previous-cancer death.  The excluded patients, 
especially those with multiple previous tumors, could have had long lead times that would have 
strongly influenced estimates in the original analysis.  The large difference between these results 
indicates that competing risks are a likely source of bias in future studies about the survival of 
patients with multiple cancers. 
We estimated the lung cancer lead time to be short.  In coming years, as lung cancer 
screening becomes more routine, lead time for lung cancer in patients with previous cancers may 
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increase.  In patients with previous cancer who go on to develop other cancer types with 
recommended early detection methods, such as breast, cervical, and colorectal cancer, lead times 
may be larger.  As our proposed model handles bias from both competing risks and lead time, we 
advocate its application in future studies about the prognosis of cancer patients with multiple 
cancers. 
Several studies have applied the Fine-Gray18 competing-risk model to analyze the mortality 
of cancer patients with a history of previous cancer.61,62  To our knowledge, none has proposed a 
discrete competing-risk model and none has further adjusted for lead-time bias.  
Our study has some limitations.  First, SEER records a limited set of baseline variables, and 
the absence of possible confounders may bias our estimates of the odds ratios on the cause-
specific hazards.  Most prominently, SEER does not include smoking status, which is associated 
with lung cancer, other cancers, and survival.  Second, to reduce confounding, we applied our 
model to matched data.  This simplified computations but prevented us from assessing the effects 
of these variables on mortality.  Future studies could consider hazard models that include these 
predictors, both as a way to better describe mortality and to exploit all available observations.  
Third, we did not differentiate the types of previous cancers.  Clearly, the previous cancer type is 
a powerful predictor of survival; early-stage breast cancer has a far better prognosis than, say, 
advanced pancreatic cancer.62,63  Finally, our analysis relies on assumptions regarding the form 
of the joint distribution of the latent lead time and post-lead time survival.  Previous analyses 
with a similar model, however, suggested that conclusions are only moderately sensitive to these 
untestable assumptions.52 
In conclusion, under a discrete competing-risk model, the estimated mean lead time is less 
than one month for all stages of lung cancer.  Both with and without adjustment for lead time, the 
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Previous group had a significantly lower hazard for both lung cancer and non-cancer mortality.  
Evidently, the different survival outcomes seen in the Previous and No-Previous groups 
represent true differences in mortality, and not a lead-time bias. 
 The number of cancer survivors in the U.S. is large and growing; as life expectancy for this 
population increases,63 the U.S. will face a rising number of patients diagnosed with multiple 
primary cancers.  Careful consideration of the prevalence and impact of multiple primary cancers 
on cancer outcomes is needed to ensure accurate estimation of mortality in descriptive cancer 
epidemiology.  More importantly exclusion criteria in lung cancer clinical trials, which 
frequently prevent participation of patients with previous cancer,2 should be carefully 
reconsidered in light of the observed survival advantage for lung cancer and non-cancer cause of 
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Table S1.  Characteristics of patients with stage III lung cancer. 
 
 
n (%) P value 
Previous No-Previous Matched No-Previous Unmatched Matched 
Total (n) 6250 43834 6250   
      
Age    <0.0001 0.65 
<75 2383 (38.1) 20128 (45.9) 2391 (38.3)   
75–85 2996 (47.9) 18667 (42.6) 3023 (48.4)   
≥85 871 (13.9) 5039 (11.5) 836 (13.4)   
      
Sex    <0.0001 0.93 
Female 2424 (38.8) 20586 (47.0) 2429 (38.9)   
Male 3826 (61.2) 23248 (53.0) 3821 (61.1)   
      
Race    0.00084 0.76 
White 5415 (86.6) 37360 (85.2) 5455 (87.3)   
Black 550 (8.8) 3975 (9.1) 520 (8.3)   
Hispanic 44 (0.7) 487 (1.1) 42 (0.7)   
Other 241 (3.9) 2012 (4.6) 233 (3.7)   
      
Marital Status    <0.0001 0.92 
Married 3371 (53.9) 21471 (49.0) 3377 (54.0)   
Sep/div/wid 2278 (36.4) 17626 (40.2) 2257 (36.1)   
Single 406 (6.5) 3162 (7.2) 424 (6.8)   
Unknown 195 (3.1) 1575 (3.6) 192 (3.1)   
      
Histology    <0.0001 0.56 
Adenocarcinoma 2264 (36.2) 13731 (31.3) 2244 (35.9)   
Squamous 1535 (24.6) 11095 (25.3) 1484 (23.7)   
Small cell 785 (12.6) 6288 (14.3) 819 (13.1)   
NSCLS/other 1666 (26.7) 12720 (29.0) 1703 (27.2)   
      
Charlson Score    <0.0001 0.66 
0 2369 (37.9) 16408 (37.4) 2405 (38.5)   
1 1851 (29.6) 12864 (29.3) 1849 (29.6)   
2+ 1813 (29.0) 11957 (27.3) 1802 (28.8)   
Unavailable 217 (3.5) 2605 (5.9) 194 (3.1)   
      
Medicaid    <0.0001 0.40 
Yes 877 (14.0) 8646 (19.7) 910 (14.6)   
No 5373 (86.0) 35188 (80.3) 5340 (85.4)   
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Lung cancer treatment    0.028 0.88 
Surgery only 326 (5.2) 2184 (5.0) 340 (5.4)   
Chemotherapy only 710 (11.4) 4451 (10.2) 702 (11.2)   
Radiation only 984 (15.7) 6782 (15.5) 949 (15.2)   
≥2 treatments 2170 (34.7) 15580 (35.5) 2170 (34.7)   
No surg/chemo/rad 2060 (33.0) 14837 (33.8) 2089 (33.4)   
 
 
Table S2. Characteristics of patients with stage IV lung cancer. 
 n (%) P value Previous No-Previous Matched No-Previous Unmatched Matched 
Total (n) 9715 70842 9715   
      
Age    <0.0001 0.88 
<75 3822 (39.3) 33932 (47.9) 3820 (39.3)   
75–85 4651 (47.9) 29571 (41.7) 4649 (47.9)   
≥85 1242 (12.8) 7339 (10.4) 1246 (12.8)   
      
Sex    <0.0001 0.17 
Female 3622 (37.3) 33233 (46.9) 3591 (37.0)   
Male 6093 (62.7) 37609 (53.1) 6124 (63.0)   
      
Race    0.00028 0.99 
White 8387 (86.3) 60596 (85.5) 8410 (86.6)   
Black 859 (8.8) 6055 (8.5) 830 (8.5)   
Hispanic 94 (1.0) 846 (1.2) 94 (1.0)   
Other 375 (3.9) 3345 (4.7) 381 (3.9)   
      
Marital Status    <0.0001 0.77 
Married 5284 (54.4) 34619 (48.9) 5290 (54.5)   
Sep/div/wid 3454 (35.6) 27864 (39.3) 3453 (35.5)   
Single 656 (6.8) 5814 (8.2) 665 (6.8)   
Unknown 321 (3.3) 2545 (3.6) 307 (3.2)   
      
Histology    <0.0001 0.98 
Adenocarcinoma 3336 (34.3) 22742 (32.1) 3296 (33.9)   
Squamous 1530 (15.7) 10239 (14.5) 1532 (15.8)   
Small cell 1668 (17.2) 13212 (18.6) 1641 (16.9)   
NSCLS/other 3181 (32.7) 24649 (34.8) 3246 (33.4)   
      
Charlson Score    <0.0001 0.72 
0 3946 (40.6) 28555 (40.3) 3991 (41.1)   
1 2772 (28.5) 19864 (28.0) 2763 (28.4)   
2+ 2649 (27.3) 17371 (24.5) 2592 (26.7)   
Unavailable 348 (3.6) 5052 (7.1) 369 (3.8)   
      
Medicaid    <0.0001 1.0 
Yes 1372 (14.1) 13365 (18.9) 1378 (14.2)   
No 8343 (85.9) 57477 (81.1) 8337 (85.8)   
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Lung cancer treatment    <0.0001 0.86 
Surgery only 150 (1.5) 909 (1.3) 151 (1.6)   
Chemotherapy only 1502 (15.5) 9948 (14.0) 1445 (14.9)   
Radiation only 2058 (21.2) 15142 (21.4) 2093 (21.5)   
≥2 treatments 2261 (23.3) 16143 (22.8) 2275 (23.4)   
No surg/chemo/rad 3744 (38.5) 28700 (40.5) 3751 (38.6)   
 
 
Figure S1. Cumulative incidence rate by stage and cause of death in the two-cause data for lung 




Table S3. Estimated mean lead time (months) and odds ratios by cause of death and stage in the 
two-cause competing risk data. 
Lung cancer 
stage Mean lead time (95% CI) ORl (95% CI) ORo (95% CI) 
 Assuming lead time 
I&II 0.60 (0.11, 1.10) 0.90 (0.87, 0.94) 1.41 (1.34, 1.48) 
III 0.76 (0, 1.55) 0.94 (0.89, 0.99) 1.59 (1.48, 1.71) 
IV 0.43 (0.09, 0.77) 0.87 (0.83, 0.91) 1.64 (1.54, 1.74) 
 Assuming no lead time 
I&II 0 0.88 (0.85, 0.92) 1.39 (1.33, 1.46) 
III 0 0.89 (0.86, 0.92) 1.51 (1.43, 1.60) 
IV 0 0.82 (0.80, 0.84) 1.56 (1.49, 1.64) 
ORl:  Odds ratio of the lung cancer mortality hazard of the Previous group relative to the No-Previous group.   
ORo:  Odds ratio of the other (non-cancer and previous cancer) mortality hazard of the Previous group relative to the 
No-Previous group. 
 
